Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease.

MLA

Schwartz, Gregory G., et al. “Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease.” Diabetes Care, vol. 43, no. 5, May 2020, pp. 1077–84. EBSCOhost, https://doi.org/10.2337/dc19-2204.

APA

Schwartz, G. G., Leiter, L. A., Ballantyne, C. M., Barter, P. J., Black, D. M., Kallend, D., Laghrissi-Thode, F., Leitersdorf, E., McMurray, J. J. V., Nicholls, S. J., Olsson, A. G., Preiss, D., Shah, P. K., Tardif, J.-C., & Kittelson, J. (2020). Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. Diabetes Care, 43(5), 1077–1084. https://doi.org/10.2337/dc19-2204

Chicago

Schwartz, Gregory G., Lawrence A. Leiter, Christie M. Ballantyne, Philip J. Barter, Donald M. Black, David Kallend, Fouzia Laghrissi-Thode, et al. 2020. “Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease.” Diabetes Care 43 (5): 1077–84. doi:10.2337/dc19-2204.